Polymicrobial septic arthritis in a patient with Wilson’s disease
Polymicrobial septic arthritis in a patient with Wilson’s disease
复制标题
DOI：
10.1136/ard.62.7.693
复制
发表时间：
2003-07
影响因子：
27.4
通讯作者：
J-W Chung;Y. Suh;J-H Choi;H-S Park;J-H Won;C. Suh
中科院分区：
文献类型：
--
作者：
J-W Chung;Y. Suh;J-H Choi;H-S Park;J-H Won;C. Suh
英夫利西单抗是一种人源化、小鼠源性、基因工程的抗肿瘤坏死因子α（TNFα）单克隆抗体，已成功与低剂量甲氨蝶呤联合用于治疗类风湿性关节炎（RA）。1据报道，严重感染与英夫利西单抗治疗有关。1，2然而，英夫利西单抗在慢性病毒感染中的安全性尚不清楚或尚未确定，包括人免疫缺陷病毒、B型肝炎病毒（HBV）或C型肝炎病毒感染。我们描述了一个病例，来自我们的队列102例患者接受英夫利西单抗联合甲氨蝶呤治疗，谁携带乙肝B表面抗原（HBsAg），随后发展为急性肝炎，由于HBV再激活后16个月的英夫利西单抗治疗。一位49岁的男性在1990年1月被诊断为RA。结论：乙型肝炎病毒表面抗原（HBsAg）、乙型肝炎病毒e（HBe）、乙型肝炎病毒c（HBc）抗体阳性，乙型肝炎病毒e（HBe）抗原、乙型肝炎病毒表面抗原（HBs）阳性。
Infliximab, a humanised, mouse derived, genetically engineered, monoclonal antibody to tumour necrosis factor α (TNFα), is successfully used in association with low dose methotrexate in the treatment of rheumatoid arthritis (RA).1 Serious infections have been reported to be associated with infliximab treatment.1,2 However, the safety of infliximab is unknown or has not been yet established in chronic viral infections, including human immunodeficiency virus, hepatitis B virus (HBV) or hepatitis C virus infections. We describe a case, from our cohort of 102 patients treated with infliximab plus methotrexate, who carried hepatitis B surface antigen (HBsAg) and subsequently developed acute hepatitis due to HBV reactivation after 16 months of treatment with infliximab. A 49 year old man was diagnosed as having RA in January 1990. HBsAg, and HBe and HBc antibodies were positive, while HBe antigen and HBs …